ReP USP - Resultado da busca

Artigo de periodico
Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline (2020)
Apolinário, Alexsandra Conceição ; Hirata, Amanda Soares ; Miguel, Rodrigo dos Anjos ; Costa-Lotufo, Letícia Veras ; Pessoa Junior, Adalberto ; Clair, James J. La ; Fenical, William ; Lopes, Luciana Biagini
Source: Nanomedicine. Unidades: ICB, FCF
Subjects: FARMACOLOGIA, NEOPLASIAS MAMÁRIAS, NANOTECNOLOGIA, ANTINEOPLÁSICOS, QUIMIOTERÁPICOS, MELANOMA, FARMACOS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
APOLINÁRIO, Alexsandra Conceição et al. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline. Nanomedicine, v. 15, n. 26, p. 2539–2542, 2020Tradução . . Disponível em: https://doi.org/10.2217/nnm-2020-0290. Acesso em: 03 nov. 2024.
APA
Apolinário, A. C., Hirata, A. S., Miguel, R. dos A., Costa-Lotufo, L. V., Pessoa Junior, A., Clair, J. J. L., et al. (2020). Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline. Nanomedicine, 15( 26), 2539–2542. doi:10.2217/nnm-2020-0290
NLM
Apolinário AC, Hirata AS, Miguel R dos A, Costa-Lotufo LV, Pessoa Junior A, Clair JJL, Fenical W, Lopes LB. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline [Internet]. Nanomedicine. 2020 ; 15( 26): 2539–2542.[citado 2024 nov. 03 ] Available from: https://doi.org/10.2217/nnm-2020-0290
Vancouver
Apolinário AC, Hirata AS, Miguel R dos A, Costa-Lotufo LV, Pessoa Junior A, Clair JJL, Fenical W, Lopes LB. Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline [Internet]. Nanomedicine. 2020 ; 15( 26): 2539–2542.[citado 2024 nov. 03 ] Available from: https://doi.org/10.2217/nnm-2020-0290
Trabalho de evento-resumo periodico
Integrative toxicogenomic and system biology platforms to target melanoma genes by DM-1 (2016)
Oliveira, Erica Aparecida de; Souza, Garcia Ferreira de; Lima, Diógenes Saulo de; Cardozo, Lucas Esteves; Faião-Flores, Fernanda; Suárez, José Agustín Pablo Quincoces; Nakaya, Helder Takashi Imoto ; Monteiro, Gisele ; Maria-Engler, Silvya Stuchi
Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Sciences and Technology Meeting of the Faculty of Pharmaceutical Sciences, University of São Paulo. Unidade: FCF
Subjects: MELANOMA, BIOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Erica Aparecida de et al. Integrative toxicogenomic and system biology platforms to target melanoma genes by DM-1. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 03 nov. 2024. , 2016
APA
Oliveira, E. A. de, Souza, G. F. de, Lima, D. S. de, Cardozo, L. E., Faião-Flores, F., Suárez, J. A. P. Q., et al. (2016). Integrative toxicogenomic and system biology platforms to target melanoma genes by DM-1. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Oliveira EA de, Souza GF de, Lima DS de, Cardozo LE, Faião-Flores F, Suárez JAPQ, Nakaya HTI, Monteiro G, Maria-Engler SS. Integrative toxicogenomic and system biology platforms to target melanoma genes by DM-1. Brazilian Journal of Pharmaceutical Sciences. 2016 ; 52 14 res. FCF024.[citado 2024 nov. 03 ]
Vancouver
Oliveira EA de, Souza GF de, Lima DS de, Cardozo LE, Faião-Flores F, Suárez JAPQ, Nakaya HTI, Monteiro G, Maria-Engler SS. Integrative toxicogenomic and system biology platforms to target melanoma genes by DM-1. Brazilian Journal of Pharmaceutical Sciences. 2016 ; 52 14 res. FCF024.[citado 2024 nov. 03 ]
Artigo de periodico
BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity (2016)
Ferreira, Adilson Kleber; Pasqualoto, Kerly Fernanda Mesquita; Kruyt, Frank A. E; Berl, Fanny Palace; Azevedo, Ricardo Alexandre de; Turra, Kely Medeiros; Rodrigues, Cecília Pessoa; Ferreira, Ana Carolina Franco; Salomon, Maria Alejandra Clavijo; Sá Júnior, Paulo Luiz de; Farias, Camyla Fernandes; Figueiredo, Carlos Rogério; Tavares, Leoberto Costa ; Barbuto, José Alexandre Marzagão ; Jorge, Salomão Dória
Source: Toxicology and Applied Pharmacology. Unidades: FCF, ICB
Subjects: MELANOMA, METÁSTASE NEOPLÁSICA, APOPTOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERREIRA, Adilson Kleber et al. BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity. Toxicology and Applied Pharmacology, v. 295, p. 56-67, 2016Tradução . . Disponível em: https://doi.org/10.1016/j.taap.2016.02.008. Acesso em: 03 nov. 2024.
APA
Ferreira, A. K., Pasqualoto, K. F. M., Kruyt, F. A. E., Berl, F. P., Azevedo, R. A. de, Turra, K. M., et al. (2016). BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity. Toxicology and Applied Pharmacology, 295, 56-67. doi:10.1016/j.taap.2016.02.008
NLM
Ferreira AK, Pasqualoto KFM, Kruyt FAE, Berl FP, Azevedo RA de, Turra KM, Rodrigues CP, Ferreira ACF, Salomon MAC, Sá Júnior PL de, Farias CF, Figueiredo CR, Tavares LC, Barbuto JAM, Jorge SD. BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity [Internet]. Toxicology and Applied Pharmacology. 2016 ; 295 56-67.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.taap.2016.02.008
Vancouver
Ferreira AK, Pasqualoto KFM, Kruyt FAE, Berl FP, Azevedo RA de, Turra KM, Rodrigues CP, Ferreira ACF, Salomon MAC, Sá Júnior PL de, Farias CF, Figueiredo CR, Tavares LC, Barbuto JAM, Jorge SD. BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity [Internet]. Toxicology and Applied Pharmacology. 2016 ; 295 56-67.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.taap.2016.02.008
Artigo de periodico
Benzofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo (2015)
Farias, C. F; Massaoka, Mariana H; Girola, N; Azevedo, R. A; Ferreira, A. K; Jorge, S. D; Tavares, Leoberto Costa ; Figueiredo, C. R; Travassos, L. R
Source: BMC Cancer. Unidade: FCF
Subjects: MELANOMA, APOPTOSE, PROTEÍNAS QUINASES, NEOPLASIAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FARIAS, C. F et al. Benzofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo. BMC Cancer, v. 15, p. art. 807 1-11, 2015Tradução . . Disponível em: https://doi.org/10.1186/s12885-015-1835-3. Acesso em: 03 nov. 2024.
APA
Farias, C. F., Massaoka, M. H., Girola, N., Azevedo, R. A., Ferreira, A. K., Jorge, S. D., et al. (2015). Benzofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo. BMC Cancer, 15, art. 807 1-11. doi:10.1186/s12885-015-1835-3
NLM
Farias CF, Massaoka MH, Girola N, Azevedo RA, Ferreira AK, Jorge SD, Tavares LC, Figueiredo CR, Travassos LR. Benzofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo [Internet]. BMC Cancer. 2015 ; 15 art. 807 1-11.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1186/s12885-015-1835-3
Vancouver
Farias CF, Massaoka MH, Girola N, Azevedo RA, Ferreira AK, Jorge SD, Tavares LC, Figueiredo CR, Travassos LR. Benzofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo [Internet]. BMC Cancer. 2015 ; 15 art. 807 1-11.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1186/s12885-015-1835-3
Trabalho de evento-resumo periodico
Nifuroxazde halogenic derivatives induce ROS-mediated apoptosis and display antitumor activity against metastatic melanoma (2014)
Fernandez de Farias, C; Massaoka, Mariana Hiromi; Girola, N; Figueiredo, C. R; Azevedo, R. A; Tavares, Leoberto Costa ; Travassos, L. R
Source: European Journal of Cancer. Conference titles: EORTC - NCI - AACR Symposium on Molecular Targets and Cancer Therapeutics. Unidade: FCF
Subjects: MELANOMA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDEZ DE FARIAS, C et al. Nifuroxazde halogenic derivatives induce ROS-mediated apoptosis and display antitumor activity against metastatic melanoma. European Journal of Cancer. Oxford: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 03 nov. 2024. , 2014
APA
Fernandez de Farias, C., Massaoka, M. H., Girola, N., Figueiredo, C. R., Azevedo, R. A., Tavares, L. C., & Travassos, L. R. (2014). Nifuroxazde halogenic derivatives induce ROS-mediated apoptosis and display antitumor activity against metastatic melanoma. European Journal of Cancer. Oxford: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Fernandez de Farias C, Massaoka MH, Girola N, Figueiredo CR, Azevedo RA, Tavares LC, Travassos LR. Nifuroxazde halogenic derivatives induce ROS-mediated apoptosis and display antitumor activity against metastatic melanoma. European Journal of Cancer. 2014 ; 50 26 res. 64.[citado 2024 nov. 03 ]
Vancouver
Fernandez de Farias C, Massaoka MH, Girola N, Figueiredo CR, Azevedo RA, Tavares LC, Travassos LR. Nifuroxazde halogenic derivatives induce ROS-mediated apoptosis and display antitumor activity against metastatic melanoma. European Journal of Cancer. 2014 ; 50 26 res. 64.[citado 2024 nov. 03 ]

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Subjects

Indexado em